KBC Group
BIO icon

KBC Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

KBC Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$442K Hold
1,169
– – ﹤0.01% 800
2026
Q2 		$343K Hold
1,169
– – ﹤0.01% 876
2026
Q1 		$326K Hold
1,169
– – ﹤0.01% 853
2025
Q4 		$354K Sell
1,169
-293
-20% -$91.4K ﹤0.01% 764
2025
Q3 		$410K Hold
1,462
– – ﹤0.01% 730
2025
Q2 		$353K Buy
1,462
+165
+13% +$39K ﹤0.01% 738
2025
Q1 		$316K Sell
1,297
-984
-43% -$296K ﹤0.01% 836
2024
Q4 		$749K Sell
2,281
-814
-26% -$276K ﹤0.01% 778
2024
Q3 		$1.04M Buy
3,095
+1,400
+83% +$445K ﹤0.01% 682
2024
Q2 		$463K Sell
1,695
-557
-25% -$162K ﹤0.01% 730
2024
Q1 		$779K Sell
2,252
-1,044
-32% -$343K ﹤0.01% 692
2023
Q4 		$1.06M Sell
3,296
-1,534
-32% -$481K ﹤0.01% 681
2023
Q3 		$1.73M Sell
4,830
-548
-10% -$211K 0.01% 607
2023
Q2 		$2.04M Buy
5,378
+1,781
+50% +$725K 0.01% 600
2023
Q1 		$1.72M Sell
3,597
-284
-7% -$133K 0.01% 666
2022
Q4 		$1.63M Buy
3,881
+2,263
+140% +$913K 0.01% 636
2022
Q3 		$675K Buy
1,618
+28
+2% +$14K ﹤0.01% 716
2022
Q2 		$787K Buy
1,590
+80
+5% +$41.7K ﹤0.01% 690
2022
Q1 		$850K Sell
1,510
-29,581
-95% -$17.8M ﹤0.01% 722
2021
Q4 		$23.5M Sell
31,091
-1,844
-6% -$1.38M 0.08% 242
2021
Q3 		$24.6M Buy
32,935
+29,143
+769% +$21.8M 0.09% 228
2021
Q2 		$2.44M Buy
3,792
+673
+22% +$410K 0.01% 625
2021
Q1 		$1.78M Buy
3,119
+779
+33% +$461K 0.01% 665
2020
Q4 		$1.36M Hold
2,340
– – 0.01% 712
2020
Q3 		$1.21M Sell
2,340
-34,372
-94% -$17.4M 0.01% 679
2020
Q2 		$16.6M Buy
36,712
+17,420
+90% +$7.69M 0.11% 185
2020
Q1 		$6.76M Buy
19,292
+17,723
+1,130% +$6.52M 0.06% 309
2019
Q4 		$581K Buy
+1,569
New +$553K ﹤0.01% 1064
2015
Q4 		– Sell
-2,232
Closed -$300K – 1266
2015
Q3 		$300K Buy
+2,232
New +$321K 0.01% 904

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $63.7B AUM 20.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Ariel Investments
Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return

KBC Group's BIO Position: Q3 2026 in Review

KBC Group held its Bio-Rad Laboratories Class A (BIO) position steady in Q3 2026 at 1,169 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #800.

KBC Group first reported a position in BIO in Q3 2015 and has held it in 29 quarters since. The position peaked at $24.6M in Q3 2021. 327 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • KBC Group held 1,169 shares of Bio-Rad Laboratories Class A worth $442K as of Q3 2026.
  • KBC Group left its Bio-Rad Laboratories Class A share count unchanged in Q3 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #800 holding.
  • KBC Group first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and has held it in 29 quarters since.
  • KBC Group's Bio-Rad Laboratories Class A position peaked at $24.6M in Q3 2021.
  • 327 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.